Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sequent Medical

Request full access

Sequent Medical - Treating aneurysm with Microbraid technology

Aliso Viejo, United StatesFounded 2007Biotech & Life Sciences

About Sequent Medical

Sequent Medical, Inc., established in 2007 by co-founders Brian J. Cox and Bob Rosenbluth, Ph.D., operated as a venture-backed medical device company focused on the neurovascular market. The founders had prior success, having also established MicroVention, Inc., which was later acquired by Terumo. Sequent Medical secured significant venture capital, raising $65.3 million over several funding rounds from investors including Delphi Ventures, USVP, and Versant Ventures, to fuel its development programs.

The company's core business centered on the development, manufacturing, and sale of catheter-based devices for treating cerebral aneurysms. Its flagship product is the WEB® Aneurysm Embolization System, an intrasaccular flow disrupter designed for both ruptured and unruptured intracranial aneurysms. This system is based on the company's proprietary MicroBraid™ technology, which involves a dense mesh constructed from a large number of very fine Nitinol wires. This design allows for a tailored balance of compliance and porosity, bridging the neck of the aneurysm to promote rapid stasis. The WEB system was developed as an alternative for difficult-to-treat aneurysms, such as wide-necked bifurcation aneurysms, offering physicians a less complex, intra-saccular approach.

A significant milestone was achieved in 2010 when the WEB® system received the CE Mark, allowing for its commercial sale in major European markets. By 2016, the device had been used to treat over 3,000 patients in Europe and other regions. The company also initiated multiple clinical studies, including the WEB-IT pivotal trial to support FDA evaluation for the U.S. market and the CLARYS study in Europe to specifically assess the device's performance in ruptured aneurysms. In June 2016, Terumo Corporation announced its acquisition of Sequent Medical for an initial price of $280 million, with an additional $100 million contingent on specific milestones. The acquisition was completed in July 2016, integrating Sequent into Terumo's MicroVention subsidiary to strengthen its global neurovascular product portfolio.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2007
Headquarters
Aliso Viejo, United States
Employees
16
Open positions
None listed
Dealroom signal
77.2/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Jun 2016 $280M — Undisclosed —
SERIES DOther financing Apr 2014 $20M $80M Versant Ventures · Delphi Ventures · Domain Associates —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Sequent Medical website traffic

Latest recorded traffic for Sequent Medical is 130 monthly website visits, down 59.4% over the last three months. Sequent Medical's team grew 0% over the past year.

Latest monthly visits130 3-month web change-59.4% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sequent Medical in the Aliso Viejo ecosystem

Live from Dealroom

The Sequent Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Series B and later1 investor entered at this stage

  • Delphi Ventures
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States62.5%
🇳🇱 Netherlands12.5%
🇫🇷 France12.5%
🇮🇳 India12.5%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sequent Medical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sequent Medical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.